Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Emerging mutations in the SARS-CoV-2 variants and their role in antibody escape to small molecule-based therapeutic resistance
Chiranjib Chakraborty1, Manojit Bhattacharya2 and Ashish Ranjan Sharma3

Abstract
Several clinical trials started during the COVID-19 pandemic to discover effective therapeutics led to identify a few candidates from the major clinical trials. However, in the past several months, quite a few SARS-CoV-2 variants have emerged with significant mutations. Major mutations in the S-glycoprotein and other parts of the genome have led to the antibody’s escape to small molecule-based therapeutic resistance. The mutations in S-glycoprotein trigger the antibody escape/resistance, and mutations in RdRp might cause remdesivir resistance. The article illustrates emerging mutations that have resulted in antibody escape to therapeutics resistance. In this direction, the article illustrates presently developed neutralizing antibodies (with their preclinical, clinical stages) and antibody escapes and associated mutations. Finally, owing to the RdRp mutations, the antiviral small molecules resistance is illustrated.

Addresses
1 Department of Biotechnology, School of Life Science and Biotechnology, Adamas University, Barasat-Barrackpore Rd, Kolkata, West Bengal 700126, India
2 Department of Zoology, Fakir Mohan University, Vyasa Vihar, Balasore 756020, Odisha, India
3 Institute for Skeletal Aging & Orthopedic Surgery, Hallym University-Chuncheon Sacred Heart Hospital, Chuncheon-si, 24252, Gangwon-do, Republic of Korea

Corresponding author: Chakraborty, Chiranjib (drchiranjib@yahoo.com)

Current Opinion in Pharmacology 2022, 62:64–73
This review comes from a themed issue on Anti-infectives (2022)
Edited by Nora A. Fierro, Santiago Mirazo and Jesus Torres-Flores
For complete overview about the section, refer Anti-infectives (2022)
Available online 22 November 2021
https://doi.org/10.1016/j.coph.2021.11.006
1471-4892/© 2021 Elsevier Ltd. All rights reserved.

Introduction
Recently, several SARS-CoV-2 variants have emerged in the last several months due to SARS-CoV-2 evolution [1–3]. At the same time, WHO (World Health Organization), CDC (Centers for Disease Control and Prevention), USA (United States of America), and ECDC (European Centre for Disease Prevention and Control) have entitled the significant variants as VOC (Variant of Concern) or VOI (Variant of Interest) considering the current epidemiological status and risk. WHO has entitled the significant variants as Alpha, Gamma, Epsilon, Beta, Theta, Delta, Delta Plus, Iota, Eta, Kappa, Lambda, and so on. Some significant VOCs are Alpha variant (B.1.1.7 lineage; initially observed in the UK), Beta variant (B.1.351 lineage; first observed in South Africa), Gamma variant (P1 lineage; initially noted in Brazil), and Delta variant (B.1.617.2 lineage; initially recorded in India). At the same time, some VOIs are Epsilon variant (B.1.427/B.1.429 lineage; initially detected in the USA), Zeta variant (P2 lineage; initial observed in Brazil), Iota variant (B.1.526 lineage; initial observed in the USA) and Eta variant (B.1.525 lineage; initial observed in the USA) [2,4]. Researchers noticed the variants in the last quarter of the year 2020 with some changed features such as augmented transmissibility, increased disease severity, and immune escape property. Simultaneously, different mutations have been acquired from time to time during the generation of the SARS-CoV-2 variants. Scientists observed significant mutations in the S-glycoprotein and other regions of the genome. Spike mutations in SARS-CoV-2 variants have gained more attention because of the association with changes in viral characteristics [5].

Significant spike mutations (D614G, E484K, K417N/T, N501Y, L452R, T478K) are found associated with different clinical consequences throughout the globe [6]. Scientists observed successful therapeutics from the significant clinical trials, including small antiviral molecules such as remdesivir or antibody-based therapeutics against SARS-CoV-2 [7]. Several antibodies have shown significant neutralization activity against the virus. Some antibodies have received EUA (Emergency Use Authorization) for the treatment of this virus. Most of the antibodies are designed against the S-glycoprotein of this virus. Therefore, any S-glycoprotein mutations can trigger the antibody escapes/antibody resistance in SARS-CoV-2 variants and hinder the antibody-based therapeutic strategies against the virus.
Major SARS-CoV-2 mutations in antibody escape to therapeutic resistance Chakraborty et al. 65

[6]. At the same time, the mutations in another part of the SARS-CoV-2 genome can result in antiviral small molecules resistance. One example is Nsp12 (non-structural protein 12) mutations that might cause amino acid changes in RNA-dependent RNA polymerase (RdRp), providing remdesivir resistance.

Antiviral small molecules target the ‘protein class’of the SARS-CoV-2 virus (3C-like main protease (3CLpro) or main protease (Mpro), RdRp, Helicase (Nsp13), Spike (S)-glycoprotein), or host cell (Cathepsin L, Furin, Transmembrane Serine Protease 2 (TMPRSS2) and Angiotensin-Converting Enzyme 2 (ACE2) receptor) [8]. The S-glycoprotein interacts with the ACE2 receptor for the SARS-CoV-2 entry into the host cell. Therefore, S-glycoprotein is a significant drug target for the drug discovery of small antiviral molecules. These molecules act as viral entry inhibitors [9]. At the same time, due to the high antigenicity of S-glycoprotein, antibodies interact with the S-glycoprotein. Therefore, several vaccines have been developed using the S-glycoprotein or its components [10,11].

This article illustrates emerging mutations that result in antibody escape and therapeutic resistance. In this direction, neutralizing antibodies (nAbs) against SARS-CoV-2, their preclinical and clinical developmental stages have been discussed. The article exemplifies antibody escapes due to emerging mutations in SARS-CoV-2 variants. The small antiviral molecules resistance by the mutations in RdRp of the virus has also been described. Finally, significant mutations in the variants have been discussed to properly understand the antibody escape and small molecule-based therapeutic resistance.

Neutralizing antibodies for COVID-19 and antibody escape due to emerging mutations in SARS-CoV-2 variants

nAb might hinder virus entry through their neutralization. It is known that the natural infection or vaccination helps to generate the nAbs production in our body. nAb has been used to treat different viruses from time to time, such as influenza virus, Ebola virus, respiratory syncytial virus, HIV. There are some advantages of nAb such as low toxicity, high affinity to target proteins, and high-level specificity to antigen [12]. Recently, it was noted that nAb could protect from COVID-19, which can be generated through the vaccination against SARS-CoV-2 [12,13]. Simultaneously, nAb has also been isolated from COVID-19 infected patients for therapeutic purposes.

Neutralizing antibodies against SARS-CoV-2

When SARS-CoV-2 spread, and the pandemic started, scientists isolated nAbs from SARS-CoV-2 from patients with COVID-19 [14,15]. At first, researchers tried to understand the complexities of S-glycoprotein and the S1 and S2 subunit that activate virus fusion. In the S1 subunit, the RBD (receptor binding domain) binds with the host ACE2. Using this understanding, scientists have discovered several potent nAbs. Some of the discovered nAb against SARS-CoV-2 are B38 [16], CV30 [17], and C121 [18]. Developed nAbs were divided into different classes concerning the conformational binding to the target protein (Figure 1). Class 1 nAbs blocks the ACE2 binding against SARS-CoV-2. More specifically, these nAbs binds with the ‘open up’ conformation of RBDs. This class of nAb contains heavy chains encoded by gene segments such as VH3-52 and VH3-66 [19]. Class 2 nAbs can identify and interact with the RBDs both in the ‘up’ and ‘down’ conformation. While class 3 nAbs bind outside the binding site of the ACE2 [20].

Preclinical developmental stage

Some of the nAbs for COVID-19 are in the preclinical stage of development. Researchers have obtained several mAbs (monoclonal antibodies) from the B cells, which are in the preclinical stage of development. Some nAbs that are in the preclinical stage are CC6.30, CC6.29, CC12.1, P2B–2F6, P2C–1F11, 1–57, 2–7,2–15, COV2-2130, COV2-2196, BD-368-2 [12] (Table-1).

Clinical developmental stage

A few nAbs (mAbs and polyclonal IgG) against SARS-CoV-2 have entered into the different phases of clinical trials (Table-2). Some examples of nAbs that have progressed to the clinical trials are nAb LY-CoV555 and the mAb combinations of REGN10933 and REGN10987. The mAb combination (REGN10933+REGN10987) has completed the phase-III clinical trial (ClinicalTrials.gov; Clinical trial ID: NCT04426695). It has been noted that this mAb combination also shows effectiveness against the SARS-CoV-2 variants [12]. Similarly, Ly-CoV555 entered the phase-II/III clinical trial (ClinicalTrials.gov; Clinical trial ID: NCT04427501). Renowned US-based pharmaceutical company (Eli Lilly) is performing the clinical trial with two collaborators (Shanghai Junshi Bioscience and AbCellera Biologies). In phase-II clinical trial, it was found that the application of Ly-CoV555 declined the viral load in patients with COVID-19 [21].

Antibody escapes due to emerging substitution mutations in SARS-CoV-2 variants

Recently, it has been noted that different mutations might trigger the antibody escape phenomena, which causes antibody escapes/antibody resistance (Figure 2). Recently, Weisblum et al. pointed out the nAbs escape instance by SARS-CoV-2 variants. They observed some abundant mutations at the RBD and NTD (N-terminal domain). The RBD substitutions are V445E and K444 R/N/Q. While NTD substitutions are K150 R/E/T/N, K444 R/N/Q. It was observed that some mutations...
Interaction interface of a nAb (C118) with S-glycoprotein of SARS-CoV-2 (a) Figure shows the ribbon structure interaction interface of a nAb (C118) with S-glycoprotein (b) Figure shows the ribbon structure of a nAb (C118) and surface structure of S-glycoprotein (c) Interaction interface of a nAb (C118) with S-glycoprotein. The figure was generated using PDB ID: 7RKV.
(E484K, N440K, F490L, Q493K) occurred at high frequency in S-glycoprotein during the passage experiment with replication component of chimeric virus (rVSV/SARS-CoV-2/GFP). Because of the presence of these mutations, antibody escape activity is more common [22].

The same research group has performed an experiment using the replication-competent of a chimeric virus. The study used rVSV encoding a green fluorescent protein and S-glycoprotein of SARS-CoV-2 (rVSV/SARS-CoV-2/GFP) [23]. This experiment has adapted two high-titer variants of this recombinant construct (rVSV/SARS-CoV-2/GFP) and generated three to four passages. The genome was sequenced during the passage experiment (third or fourth passage), and the mutations were analyzed. Here, researchers found those mutations with high frequency in S-glycoprotein (E484K, N440K, F490L, Q493K) [22].

Another study reported C144 resistance mutations (Q493 R/K and E484 K/A/G) using SARS-CoV-2/rVSV. The study revealed that E484K substitution causes resistance to two antibodies (C051 and C052) [24]. Similarly, Hoffmann et al. observed nAbs escape by two SARS-CoV-2 variants (P1 and B.1.351). The research group observed three RBD mutations (E484K, K417N/T, and N501Y). The study reported the occurrence of total antibody escape against Bamlanivimab and partial antibody escape phenomena for Casirivimab [25]. A study by Liu et al. also reported antibody-resistant or antibody escape phenomena. They found that S477N mutation causes antibody-resistant instances to several mAbs. Similarly, E484K mutation is also responsible for antibody escape occurrence [26].

The same research group has performed an experiment using the replication-competent of a chimeric virus. The study used rVSV encoding a green fluorescent protein and S-glycoprotein of SARS-CoV-2 (rVSV/SARS-CoV-2/GFP) [23]. This experiment has adapted two high-titer variants of this recombinant construct (rVSV/SARS-CoV-2/GFP) and generated three to four passages. The genome was sequenced during the passage experiment (third or fourth passage), and the mutations were analyzed. Here, researchers found those mutations with high frequency in S-glycoprotein (E484K, N440K, F490L, Q493K) [22].

Another study reported C144 resistance mutations (Q493 R/K and E484 K/A/G) using SARS-CoV-2/rVSV. The study revealed that E484K substitution causes resistance to two antibodies (C051 and C052) [24]. Similarly, Hoffmann et al. observed nAbs escape by two SARS-CoV-2 variants (P1 and B.1.351). The research group observed three RBD mutations (E484K, K417N/T, and N501Y). The study reported the occurrence of total antibody escape against Bamlanivimab and partial antibody escape phenomena for Casirivimab [25]. A study by Liu et al. also reported antibody-resistant or antibody escape phenomena. They found that S477N mutation causes antibody-resistant instances to several mAbs. Similarly, E484K mutation is also responsible for antibody escape occurrence [26]. Similarly, class 2 antibody escape is attributed to the E484K substitution which is observed in several lineages of this virus (B.1.526 lineage, B.1.351 lineage, P1 lineage, P2 lineage, and so on). Likewise, the L452R substitution, found in B.1.617 lineage and B.1.427/429 lineage, is accountable for class 3 antibody escape. In
| Sl. No. | Name of nAb | Type of nAbs | Clinical trial No. | Status | Target site | Remarks |
|--------|------------|-------------|-------------------|--------|-------------|---------|
| 1.     | JS016      | Human mAb   | NCT04441918       | Phase I| Spike protein| Anti-SARS-CoV-2 monoclonal antibody targets spike protein and blocks binding of the virus to host cells |
| 2.     | TY027      | Engineered human IgG | NCT04429529 | Phase I completed/Phase III | SARS-CoV-2 | Used for treatment of patients with COVID-19 to slow the progression of the disease and accelerate recovery, and providing temporary protection from infection |
| 3.     | BRll-196   | Convalesced-derived human mAb | NCT04479631 | Phase I | SARS-CoV-2 | Non-overlapping epitope binding regions provide a high degree of neutralization activity against SARS-CoV-2. |
| 4.     | BRll-198   | Convalesced-derived human mAb | NCT04479644 | Phase I | SARS-CoV-2 | |
| 5.     | ABBV-47D11 | Human mAb   | NCT04644120       | Phase I| Full-length spike protein (conserved region) | The cross-neutralizing antibody targets a shared epitope on viruses and could potential for prevention and treatment of COVID-19 |
| 6.     | STI-1499   | Cocktail mAb | NCT04454398       | Phase I| Spike protein| Potent neutralizing activity against SARS-CoV-2 virus isolates, including the emerging spike D614G variant |
| 7.     | MW33       | Humanized IgG1α Ab | NCT04533048 | Phase I | Receptor-binding domain | Recombinant fully human antibody applied for patients with mild or moderate COVID-19 |
| 8.     | HFB30132A  | Recombinant mAb | NCT04590430 | Phase I | Spike protein | Fc modified IgG4 with minimized binding to the human FcγRs, which leads to decrease of risk for antibody-dependent enhancement of SARS-CoV-2 infection, |
| 9.     | ADM03820   | Cocktail mAb | NCT04592549       | Phase I| Spike protein| Mixture of two human IgG1 non-competitive binding anti-SARS-CoV-2 antibodies. |
| 10.    | HLX70      | Human mAb   | NCT04561076       | Phase I| Receptor-binding domain | Genetically engineered, fully humanized mAb that targets RBD of SARS-CoV-2 for the treatment of COVID-19 and acute respiratory disorder |
| 11.    | DZIF-10c   | Human mAb   | NCT04631705       | Phase I & Phase II | Receptor-binding domain | Intravenous infusion and by inhalation protection from virus infection in the respiratory tract. |
| 12.    | COVI-AMG   | Hamster mAb | NCT04584697       | Phase I & Phase II | Receptor-binding domain | The reduced activity and protected against the SARS-CoV-2 and the highly infectious spike (D614G) isolate. |
| 13.    | BGB DXP593 | mAb cocktails | NCT04532294 | Phase I | Spike ectodomain trimer | Overlaps with the RBD-ACE2 complex structure, and inhibiting the entrance of SARS-CoV-2 |
| 14.    | SCTA01     | Human mAb   | NCT04483375       | Phase I | Spike protein | Efficiently neutralized SARS-CoV pseudoviruses and SARS-CoV-2 by blocking the (RBD) S-protein |
| 15.    | CT-P59     | Human mAb   | NCT04525079       | Phase I | Receptor-binding domain | Reduced the viral load in the upper and lower respiratory tracts and has therapeutic potential for patients with COVID-19. |
In this study, researchers mapped all mutations using the yeast-display system and high-resolution structures of the different classes of antibodies [27]. Conversely, a reduction in the effectiveness of the bamlanivimab against the delta variant was observed [28]. The USFDA (United States Food and Drug Administration) approved the EUA of the mAb, bamlanivimab, for the COVID-19 therapy recently.
However, scientists are trying to solve the antibody escapes occurrence for flawless antibody therapy. In this direction, Miersch et al. [29] have developed tetravalent nAbs, which have shown improved effectiveness of the nAbs toward the antibody resistance or antibody escapes.

**Significant mutations and small molecule-based therapeutic resistance**

Recently, various scientists have observed several small molecule-based therapeutics resistance phenomena. Favipiravir or Remdesivir (GS-5734) are small molecule-based antiviral therapeutic, and these two molecules received EUA by the regulatory authorities from several countries to treat patients with COVID-19 [30,31]. It was noted that the RdRp (RNA-dependent RNA polymerase) is the drug target for favipiravir and remdesivir. Recently, remdesivir resistance was observed by several scientists due to the several mutations in RdRp (Figure 3). Nsp12 gene encodes the RdRp enzyme, and the polymerase structure (nsp12 polymerase) is bound with the two co-factors (nsp7 and nsp8) [32]. These two co-factors significantly trigger polymerase activity [33]. Simultaneously, the scientists reported several mutations in RdRp variants [34]. However, Mari et al. observed significant mutations in the RdRp (V557L, V473F, N491S, and F480 L/S/C) that are significantly responsible for remdesivir resistance [35]. It was noted that the V557L mutation in Nsp12 changes binding affinity to the RNA template and ultimately to remdesivir [36]. Similarly, V473F is a potential escape mutation described by Mari et al. It is one of the essential residues in the structural context of RdRp, which is associated with the fingers region. At the same time, researchers found an association between V473F mutation and an SNP, which is positioned at 24,378 genomic positions [35]. Simultaneously, scientists found that N491S in Nsp12 is associated with high-frequency nsSNPs (non-synonymous SNPs) related to escape mutations. It is also associated with the fingers region. Similarly, F480 L/S/C, another key mutation in Nsp12, is found to destabilize the interface between diverse sub-domains ('palm' and 'fingers') of the RdRp protein.

Padhi et al. [37] tried to understand the potential residues with a higher probability of mutations in remdesivir-binding sites. The study will help to understand the remdesivir-resistance phenomena. In another work, Mari et al. [38] one primary mutation (P323L) in RdRp, which might provide remdesivir resistance RdRp to the virus. A study by Szemiel et al. [39] introduced another mutation, E802D, in vitro, which reduces the remdesivir sensitivity but did not influence the replication of this virus.

**Significant mutations**

The first D614G mutation was observed during April 2020 [33]. D614G mutation is located at the S1 subunit near the S1/S2 boundary. The furin cleavage site is also found in this position (S1/S2 boundary). Later on, it was observed that the mutation has a high dN/dS ratio explaining the positive selection of the mutation [40,41]. After D614G, several other mutations were found associated with the epidemiological characteristics. The researchers reported the E484K mutation from different countries like Brazil, South Africa, and the New York, USA [42–46]. This mutation was first reported by Li et al. in September 2020. Understanding the mutation will help unfold the resistance properties to some nAb neutralizing antibodies by the virus [47]. Early 2021, another mutation, K417N, was noted from the different variants. It was found responsible for the

---

**Figure 3**

Different locations of significant mutations in RdRp that might be responsible for the remdesivir resistance (a) Different locations of the N491S, V473F, V557L mutations (b) Different locations of the P323L, F480 L/S/C, E802D. The figures were generated using PDB ID: 7BV2.
reduced antibody effectiveness elicited by the COVID-19 vaccines Pfizer-BioNTech (BNT162b2) or Moderna (mRNA-1273) [48]. At the same time, an additional mutation was found in the exact location (K417), which is K417T. The mutation K417T was found in the Gamma variant (P1 lineage) [49]. K417T/N mutation occurs due to the lack of other infrequent RBD mutations. It was reported that the K417 might decrease ACE2 binding [50]. It has been observed that the RBD mutations and NTD mutations provide antibody escape. Significant RBD mutations are K417N/T, L452R, T478K, E484K, and N501Y. Similarly, important NTD mutations include three deletions (Δ144, Δ69/70, Δ243/244) and L18F. Significant mutations that have been observed in Delta variants are L452R, T478K, and P681R (in spike protein). Similarly, scientists noted important mutations in the S-glycoprotein of Alpha variants which are Δ144, Δ69/70, N501Y, and P681H. At the same time, some significant mutations (V557L, V473F, N491S, F480 L/S/C, P323L, E802D) were found in RdRp. Those mutations might cause remdesivir resistance. However, more studies are needed in this direction.

**Conclusions**

Presently, scientists are trying to understand the most significant escape mutations or resistance mutations that might contribute to increased antibody escape especially neutralizing antibody escape or monoclonal antibody escape, and the small molecule-based therapeutic resistance. Understanding the antibody escape mutations or resistance mutations might help develop proper antibody therapeutic to avoid antibody resistance. Simultaneously, several researchers are preparing a complete mutations map in this direction. Recently, Starr et al. created a mutations map using different antibodies that might help to understand escape mutations. These mutations are present in the several variants of circulating SARS-CoV-2 [51]. At the same time, Grecan et al. developed a compressive antibody escape mutations map of RBD of S-glycoprotein. The researchers developed a deep mutational scanning technique to explain how all amino-acid mutations in the RBD influence antibody binding. Finally, they have applied the method in ten human mAb [50]. Understanding the complete escape-mutation maps in S-glycoprotein or major mutations in RdRp will help design perfect antibody therapeutics or small molecule-based therapeutic. These rationally designed therapeutics can compare the viral evolution and the antigenic consequences. The overall knowledge will help to discover more highly potent, next-generation antibody therapeutics or small molecule-based therapeutics. Finally, a robust scientific approach toward understanding the consequences of evolutionary mutations in the emerging variants will help end the present pandemic and help prepare for the next pandemic.

**Informed consent and patient details**

Not required.

**Conflict of interest statement**

 Nothing declared.

**Abbreviations**

- EUA: Emergency use authorization
- rVSV: Reombinant vesicular stomatitis virus
- RBD: Receptor binding domain
- mAb: Monoclonal Antibody
- nAb: Neutralizing Antibody
- ACE2: Angiotensin-Converting Enzyme 2
- RdRp: RNA-dependent RNA polymerase

**References**

Papers of particular interest, published within the period of review, have been highlighted as:

* of special interest
** of outstanding interest

1. Lauring AS, Hodcroft EB: Genetic variants of SARS-CoV-2—what do they mean? *JAMA* 2021, 325:529–531.
2. Chakraborty C, Sharma AR, Bhattacharya M, Agoramooorthy G, Lee S-S: Evolution, mode of transmission, and mutational landscape of newly emerging SARS-CoV-2 variants. *mBio* 2021, 12, e01140.01151.
3. This paper illustrates the newly emerging variants of SARS-CoV-2 and their mutational landscape.
4. Alem A, AB AS, Slender AK: Emerging variants of SARS-CoV-2 and novel therapeutics against coronavirus (COVID-19). In *StatPears [Internet], Treasure Island (FL)*. StatPearsPublishing; 2021.
5. Harvey WT, Carabelli AM, Jackson B, Gupta RK, Thomson EC, Harrison EM, Ludden C, Reeve R, Rambaut A, Peacock SJ: SARS-CoV-2 variants, spike mutations and immune escape. *Nat Rev Microbiol* 2021, 19:409–424.
6. This paper illustrates SARS-CoV-2 mutations such as D614G, E484K, L452R, and others. The article also describes different SARS-CoV-2 variants such as Alpha, Beta, Gamma, Delta, and their effects on nAb protection and vaccination.
7. Tao K, Tzou PL, Nouhijn J, Gupta RK, de Oliveira T, Kosakovskiy Pond SL, Fera D, Shafer RW: The biological and clinical significance of emerging SARS-CoV-2 variants. *Nat Rev Genet* 2021, 1–17.
8. Chakraborty C, Bhattacharya M, Agoramooorthy G, Lee S-S: The drug repurposing for COVID-19 clinical trials provide very effective therapeutic combinations: lessons learned from major clinical studies. *Front Pharmacol* 2021, 12: 2942, https://doi.org/10.3389/fphar.2021.704205.
9. The paper illustrates the outcome of the significant clinical trial such as from ACTT-1 and ACTT-2 study group, RECOVERY trials, etc.
10. Chakraborty C, Bhattacharya M, Agoramooorthy G, Sharma AR, Lee SS: Development of epitope-based therapeutics or small molecule-based therapeutics. A potential pharmacological insight view for the new drug development. *Exper Rev Clin Pharmacol* 2021, 14:225–237.
11. Canniale R, Stefanelli I, Cerchia C, Beccari AR, Pelliccia S, Summa V: SARS-CoV-2 entry inhibitors: small molecules and peptides targeting virus or host cells. *Int J Mol Sci* 2020, 21: 5707.
12. Bhattacharya M, Sharma AR, Patra P, Ghosh P, Sharma G, Patra BC, Lee SS, Chakraborty C: Development of epitope-based...
The significant article describes different categories of the antibodies such as Class 1, Class 3, Class 4.

21. Chen P, Nirula A, Beller B, Gottlieb RL, Bosica J, Morris J, Huhn G, Cardona J, Mocharla B, Stosor V: SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19. Nature Med 2021, 27:7–12.

22. Weissblum Y, Schmidt F, Zhang F, DaSilva J, Posnett DA, Barnes CO, Schaefer-Elowe K, Pronko P, Saha RP, Lee SS, Chakraborty C: A SARS-CoV-2 vaccine candidate: in-silico cloning and validation. Immunity 2020, 62:520–528.

23. Schmidt F, Weissblum Y, Muecksch F, Hoffmann HH, Michailidis E, Lorenzi JC, Mendoza P, Rutkowska M, Huey-Tubman KE: Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations. Proc Natl Acad Sci U S A 2021, 118:6184–6193.

24. Hoffmann M, Arora P, Groß R, Seidel A, Hörnich B, Hahn AS, Hoffmann A, Krüger N, Graichen H, Hofmann-Winkler R, Kempf A: SARS-CoV-2 variants B.1.1.7 and B.1.351 escape from neutralizing antibodies. Nature Med 2021, 27:78–83.

25. Liu Z, VanBlargan LA, Bloyet L-M, Rothlauf PW, Chen RC, Stumpf S, Zhao H, Enrico JM, Theel ES, Liebsen MJ: Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization. Cell Host Microbe 2021, 29:1–12.
VOC in SARS-CoV-2: is it part of the positive selection pioneered by Darwin? Mol Ther Nucleic Acids 2021, 26:237–241.

43. Wise J: Covid-19: the E484K mutation and the risks it poses. Brit Med J Pub Group 2021, 372:n359.

44. Chakraborty C, Saha A, Sharma AR, Bhattacharya M, Lee S-S, Agoramorthy G: D614G mutation eventuates in all VOC and VOI in SARS-CoV-2: is it part of the positive selection pioneered by Darwin? Mol Ther Nucleic Acids 2021, 26:237–241.

The article describes the natural selection D614G mutation in SARS-CoV-2 variants.

45. da Silva Francisco Jr R, Benites LF, Lamarca AP, de Almeida LG, Hansen AW, Guilete JS, Demoliner M, Gerber AL, de C Guimarães AP, Antunes AKE: Pervasive transmission of E484K and emergence of VUI-NP13L with evidence of SARS-CoV-2 co-infection events by two different lineages in Rio Grande do Sul, Brazil. Virus Res 2021, 298:198345.

46. Skidmore PT, Kaelin EA, Holland LA, Mellor NJ, Blain JM, Harris V, LaBaer J, Murugan V: Genomic sequencing of SARS-CoV-2 E484K variant B.1.1.1.241. 1, Arizona, USA. Emerg Infect Dis 2021, 27:2718.

47. Li Q, Wu J, Nie J, Zhang L, Hao H, Liu S, Zhao C, Zhang Q, Liu H, Nie L: The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity. Cell 2020, 182:1284–1294. e1289.

48. Wang Z, Schmidt F, Weisblum Y, Muecksch F, Barnes CO, Finkin S, Schaefer-Babajew D, Cipolla M, Gaebler C, Lieberman JA: mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature 2021, 592:616–622.

49. Chakraborty C, Bhattacharya M, Sharma AR, Lee S-S, Agoramorthy G: SARS-CoV-2 Brazil variant in Latin America: more serious research urgently needed on public health and vaccine protection. Annal Med Surg 2021, 66:102428.

50. Greaney AJ, Starr TN, Gilchuk P, Zost SJ, Binshtein E, Loes AN, Hilton SK, Huddleston J, Equia R, Crawford KH: Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition. Cell Host Microbe 2021, 29:44–57. e49.

51. Starr TN, Greaney AJ, Addetia A, Hannon WW, Choudhary MC, Dingens AS, Li JZ, Bloom JD: Prospective mapping of viral mutations that escape antibodies used to treat COVID-19. Science 2021, 371:850–854.

52. Liu L, Wang P, Nair MS, Yu J, Rapp M, Wang Q, Luo Y, Chan JF-W, Sahi V, Figueiroa A: Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 2020, 584:450–456.

53. Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, Wang F, Li D, Yang M, Xing L: Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. Jama 2020, 323:1582–1589.

54. Oplinger AA: Clinical trials of monoclonal antibodies to prevent COVID-19 now enrolling. National Institutes of Health 2020, 10. https://www.nih.gov/news-events/news-releases/clinical-trials monoclonal-antibodies-prevent-covid-19-now-enrolling.

55. Ju B, Zhang Q, Ge J, Wang R, Sun J, Ge X, Yu J, Shan S, Zhou B, Song S: Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature 2020, 584:115–119.

56. Biotherapeutics SA: Safety: Tolerability, and pharmacokinetics of SAB-185 in ambulatory participants with COVID-19. In ClinicalTrials.gov, 2020. https://clinicaltrials.gov/ct2/show/ NCT04469179; 2020.

57. Chi X, Yan R, Zhang J, Zhang G, Zhang Y, Hao M, Zhang Z, Fan P, Dong Y, Yang Y: A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. Science 2020, 369:650–655.

58. Wu Y, Li C, Xia S, Tian X, Kong Y, Wang Z, Gu C, Zhang R, Tu C, Xie Y: Identification of human single-domain antibodies against SARS-CoV-2. Cell Host Microbe 2020, 27:891–898. e895.

59. Vir Biotechnology I: VIR-7831 for the early treatment of COVID-19 in outpatients (COMET-ICE). 2020.

60. Hanke L, Perez LV, Sheward DJ, Das H, Schulte T, Moliner-Moro A, Corcoran M, Achour A, Hedestam GBK, Hällberg BM: An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction. Nat Commun 2020, 11:1–9.

61. Huo J, Le Bas A, Ruza RR, Duyvesteyn HM, Molinari L, Malinauskas T, Tan TK, Rijal P, Dumoux M, Ward PN: Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2. Nat Struct Mol Biol 2020, 27:846–854.

62. Pinto D, Park Y-J, Beltramello M, Walls AC, Tortorici MA, Bianchi S, Jaconi S, Culap K, Zatta F, De Marco A: Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature 2020, 583:290–295.